Recently, Dhillon et al. showed that elevated sST2 and IL-33 were both associated with increased mortality in STEMI patients [18], but in patients with NSTEMI only sST2 and not IL-33 levels were related to adverse events such as all-cause mortality, heart failure hospitalization, and reinfarction [16]. Here, IL33 is linked to heart failure.